NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Meirluc,

That’s correct. 166 OS evented (50% of the trial n=331).
ITT median isn’t a point of significance.
And the overall ITT might get worse, and there is a chance it will as not all 108 patients at the time of the analysis were 23.1 months out from surgery.

Post 184928
Your quote:
Finally, for the 100 patients the definition of long lived was never defined. It could have spanned the time lines of who knows, 24 to 70 months with a derived mOS of 40.5 months

We know 115 patients reached 24 months and 67 patients reached 30 months at the time of the analysis (March 2017) https://www.nwbio.com/dcvax-personalized-dendritic-cell-vaccines/.
You see 21 censors (maybe 22 or 20) on the graph between 24 and 30 months. I believe these censors are all patients still alive at the time of the analysis.That means that the definition of long lived patients = 100 patients reached 27 months from surgery at the time of the analysis( March 2017) (and look at the down steps)!

Your quote( post 184830):

of the 100, 65.9% had methylated MGMT? have they averaged out the degree of methylation over the entire cohort of 100 long live patients? I thought they would have a cut of point for degree of methylation that would characterize a patient as either met+ or met-.


Of 38 patients we are missing data.
Just imagine from 100 patients:

12 patients unknown.
58 patients methylated.
30 patients unmethylated.

So we have 58 X 100/88= 65,9% methylated MGMT.
And 30 X 100/88= 34,1% unmethylated MGMT.

Meirluc, of all the data we received you can calculate at what time a patient died after 23.1 month. (at the time of the analysis March 2017) Just do the calculation!
IMO